Detail akcie Silverback Therp Rg online

Business Summary: ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, ARS Pharmaceuticals Inc revenues increased from $2.6M to $56.2M. Net loss increased from $41.9M to $130M. Revenues reflect Product revenue, net increase from $568K to $51.9M, Revenue under collaboration agreements increase of 32% to $2.6M. Higher net loss reflects PHARMACEUTICAL PREPARATIONS segment loss increase from $50.3M to $138M.